Celyad Oncology reports Q3 results

Nov. 10, 2022 3:24 AM ETCelyad Oncology SA (CYAD), CLYYFBy: Meghavi Singh, SA News Editor
  • Celyad Oncology press release (NASDAQ:CYAD): Q3 as of September 30, 2022, the Company had cash and cash equivalents of €13.4M ($13.1M).
  • Net cash burn during the first quarter of 2022 amounted to €1.0M ($1.0M), in line with expectations.
  • The Company confirms its previous guidance that its existing cash and cash equivalents should be sufficient to fund operating expenses and capital expenditure requirements up to mid-2023.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.